Search Results - "Natsume, Kazuto"

Phase I study of alpelisib (BYL719), an α‐specific PI3K inhibitor, in Japanese patients with advanced solid tumors by Ando, Yuichi, Iwasa, Satoru, Takahashi, Shunji, Saka, Hideo, Kakizume, Tomoyuki, Natsume, Kazuto, Suenaga, Naoko, Quadt, Cornelia, Yamada, Yasuhide

“…This phase I study aimed to determine tolerability and preliminary efficacy of single‐agent alpelisib (BYL719) in Japanese patients with advanced solid…”
Get full text

A phase I, dose-escalation study of oral PIM447 in Japanese patients with relapsed and/or refractory multiple myeloma by Iida, Shinsuke, Sunami, Kazutaka, Minami, Hironobu, Hatake, Kiyohiko, Sekiguchi, Risa, Natsume, Kazuto, Ishikawa, Norifumi, Rinne, Mikael, Taniwaki, Masafumi

“…PIM447, a pan-proviral integration site for Moloney leukemia (PIM) kinase inhibitor, has shown preclinical activity in multiple myeloma (MM). This phase I,…”
Get full text

Efficacy and safety of tisagenlecleucel in Japanese pediatric and young adult patients with relapsed/refractory B cell acute lymphoblastic leukemia by Hiramatsu, Hidefumi, Adachi, Souichi, Umeda, Katsutsugu, Kato, Itaru, Eldjerou, Lamis, Agostinho, Andrea Chassot, Natsume, Kazuto, Tokushige, Kota, Watanabe, Yoko, Grupp, Stephan A.

“…Tisagenlecleucel is an autologous T cell genetically modified ex vivo using a lentiviral vector encoding an anti-CD19 chimeric antigen receptor. Here, we…”
Get full text

Phase I dose‐escalation study of capmatinib (INC280) in Japanese patients with advanced solid tumors by Esaki, Taito, Hirai, Fumihiko, Makiyama, Akitaka, Seto, Takashi, Bando, Hideaki, Naito, Yoichi, Yoh, Kiyotaka, Ishihara, Kae, Kakizume, Tomoyuki, Natsume, Kazuto, Myers, Andrea, Doi, Toshihiko

“…Capmatinib is a highly specific, potent and selective MET inhibitor. This was an open‐label, multicenter, dose‐escalation, phase I study conducted in Japanese…”
Get full text

A randomized dose-escalation study to assess the safety, tolerability, and pharmacokinetics of ruxolitinib (INC424) in healthy Japanese volunteers by Ogama, Yoichiro, Mineyama, Tomoko, Yamamoto, Asuka, Woo, Margaret, Shimada, Naomi, Amagasaki, Taro, Natsume, Kazuto

“…Ruxolitinib (INC424), a potent and selective oral Janus kinase 1 and 2 inhibitor, was recently approved by the US food and drug administration for the…”
Get full text

A phase I study of single-agent BEZ235 special delivery system sachet in Japanese patients with advanced solid tumors by Toyoda, Masanori, Watanabe, Koichiro, Amagasaki, Taro, Natsume, Kazuto, Takeuchi, Hiromi, Quadt, Cornelia, Shirao, Kuniaki, Minami, Hironobu

“…Purpose BEZ235 is a dual kinase inhibitor of phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin, which are key components of the PI3K…”
Get full text

Safety and Pharmacokinetics of Ruxolitinib (INC424) in Healthy Japanese Volunteers: Placebo-Controlled, Double-Blind, Dose-Escalation Phase 1 Study by Ogama, Yoichiro, Mineyame, Tomoko, Yamamoto, Asuka, Shimada, Naomi, Amagasaki, Taro, Natsume, Kazuto

“…Abstract 5162 Ruxolitinib (INC424), a potent and selective oral JAK1 and JAK2 inhibitor, demonstrated rapid and durable reductions in splenomegaly and improved…”
Get full text

Abstract A167: A phase I study of single-agent BEZ235 (SDS sachet), once- or twice-daily, in Japanese patients with advanced solid tumors by Watanabe, Koichiro, Minami, Hironobu, Otsu, Satoshi, Hirashima, Yoshinori, Morinaga, Ryotaro, Nishikawa, Kazuo, Hisamatsu, Yasushi, Mukohara, Toru, Kiyota, Naomi, Chayahara, Naoko, Toyoda, Masanori, Imamura, Yoshinori, Fujiwara, Yutaka, Quadt, Cornelia, Robson, Matthew, Natsume, Kazuto, Aoki, Takuji, Shirao, Kuniaki

“…Abstract Background: BEZ235 is an oral, ATP-competitive inhibitor that targets class l PI3K and downstream effectors mTORC1/2. In previous phase I studies in…”
Get full text

Design and synthesis of a metabolically stable and potent antitussive agent, a novel δ opioid receptor antagonist, TRK-851 by Sakami, Satoshi, Kawai, Koji, Maeda, Masayuki, Aoki, Takumi, Fujii, Hideaki, Ohno, Hiroshi, Ito, Tsuyoshi, Saitoh, Akiyoshi, Nakao, Kaoru, Izumimoto, Naoki, Matsuura, Hirotoshi, Endo, Takashi, Ueno, Shinya, Natsume, Kazuto, Nagase, Hiroshi

“…A series of naltrindole derivatives with an extra fused ring structure were synthesized, and their antitussive activities and metabolic stabilities were…”
Get full text